This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record.
1. Trial at a Glance
VICTORION-2P is a randomized, double-blind, parallel-group phase 3 study evaluating inclisiran in participants with established cardiovascular disease. The registry lists a planned enrollment of 17004 participants and a primary endpoint based on time to first occurrence of 3-point major adverse cardiovascular events.
| Feature | VICTORION-2P |
|---|---|
| Phase | Phase 3 |
| Condition | Atherosclerotic Cardiovascular Disease |
| Design | Randomized, double-blind, parallel-group |
| Allocation | Randomized |
| Primary purpose | Treatment |
| Enrollment | 17004 |
| Number of arms | 2 |
| Status | Active, not recruiting |
| Study start | 2021-11-23 |
| Primary completion date | 2027-05-10 |
| Lead sponsor | Novartis Pharmaceuticals |
| Sponsor type | Industry |
| ClinicalTrials.gov | NCT05030428 |
2. Clinical Question
The central question is whether treatment with inclisiran can affect the time to first occurrence of a confirmed 3-point major adverse cardiovascular event in participants with established atherosclerotic cardiovascular disease, compared with placebo.
Population
Participants with established cardiovascular disease and the registry-listed condition of atherosclerotic cardiovascular disease.
Intervention
Inclisiran sodium 300 mg.
Comparator
Placebo.
Primary question
Does inclisiran change the time to first occurrence of 3-point major adverse cardiovascular events compared with placebo?
3. Trial Design
Inclisiran
- Inclisiran sodium 300 mg
- Randomized treatment assignment
- Double-blind trial design
Placebo
- Placebo
- Randomized treatment assignment
- Double-blind trial design
The parallel-group structure means that participants are assigned to one of the two treatment groups and followed within that randomized assignment. The double-blind design is intended to keep treatment assignment masked during the study, reducing the potential for knowledge of assignment to affect trial conduct and assessment.
4. Endpoint
| Endpoint | Registry definition | Time frame |
|---|---|---|
| Time to First Occurrence of 3P-MACE | 3P-MACE is a confirmed composite endpoint which includes cardiovascular death, non-fatal myocardial infarction and non-fatal ischemic stroke. | From randomization to total follow-up time (up to 72 months) |
Why the endpoint is a time-to-event outcome
The registry defines the primary endpoint as time to first occurrence, rather than simply the proportion of participants who experience an event by a fixed calendar date. That distinction determines the statistical framework: participants can contribute different amounts of follow-up, and the analysis must account for both observed events and participants who have not yet experienced the endpoint at the time their follow-up ends.
Why 3P-MACE is a composite endpoint
The endpoint combines three clinically distinct events: cardiovascular death, non-fatal myocardial infarction, and non-fatal ischemic stroke. A participant is counted according to the first qualifying component event that occurs. Composite endpoints can increase the number of observed events and therefore provide more information for a time-to-event comparison, but interpretation depends on the components being clinically relevant to the research question.
5. Statistical Methodology
Time-to-event analysis
The primary endpoint is a time-to-first-event outcome. The natural statistical framework is therefore survival analysis, which evaluates the distribution of time until the first qualifying cardiovascular event while accommodating participants whose event has not occurred during their observed follow-up.
Here, S(t) represents the probability of remaining free of the first qualifying 3P-MACE event beyond time t. Participants who have not yet experienced the endpoint can remain informative through censoring.
Kaplan-Meier estimation
For a time-to-first-occurrence endpoint, Kaplan-Meier estimation can be used to describe the event-free survival experience over follow-up. The method estimates the probability of remaining free of the event at successive event times while accounting for censoring.
where di is the number of events at time ti and ni is the number at risk immediately before that time.
Hazard ratio
A randomized comparison of two time-to-event distributions is commonly summarized with a hazard ratio. The hazard ratio compares the estimated instantaneous event rates between treatment groups over the modeled follow-up.
A hazard ratio is a relative time-to-event measure. It is not the same as an absolute risk difference, a risk ratio at a particular time point, or the percentage of participants who experience benefit.
Cox proportional-hazards model
A Cox proportional-hazards model is a standard approach for estimating a hazard ratio for a time-to-first-event endpoint. Under the proportional-hazards assumption, the relative hazard between treatment groups is represented by a multiplicative effect that remains stable over time.
The proportional-hazards assumption is an important interpretive consideration. If the relative event rates change substantially over time, a single hazard ratio may summarize the data less completely than time-specific event-free estimates or other measures of treatment effect.
Log-rank comparison
A log-rank test is commonly used to compare survival distributions between randomized groups. It uses the ordering of observed event times and accounts for the number of participants at risk at each event time. For a primary time-to-first-event endpoint, this provides a direct comparison of the event-time distributions under the randomized treatment assignments.
6. Planned Analysis
The registry defines the primary endpoint as the time from randomization to the first occurrence of confirmed 3P-MACE, with follow-up extending to up to 72 months. A time-to-event analysis would typically estimate event-free survival with Kaplan-Meier methods and compare randomized treatment groups using a log-rank framework, with the treatment effect commonly summarized using a Cox proportional-hazards model and its confidence interval.
Primary estimand
The central treatment comparison concerns the time from randomization to the first confirmed occurrence of cardiovascular death, non-fatal myocardial infarction, or non-fatal ischemic stroke.
Event handling
Participants who do not experience a qualifying first event during their observed follow-up contribute censored time to the survival analysis.
Effect measure
A hazard ratio provides a relative comparison of the instantaneous event rate between randomized treatment groups.
Follow-up horizon
The registry specifies a total follow-up time of up to 72 months from randomization.
7. Statistical Methods Explained
Why is the primary endpoint analyzed as time-to-event?
Because the endpoint is defined as the time to first occurrence of 3P-MACE, the timing of an event is part of the outcome. Two participants who both experience an event do not necessarily contribute the same amount of information if their events occur at different times. Survival analysis preserves that timing information while also accommodating participants who remain event-free at the end of their observed follow-up.
Why use a composite endpoint?
The registry combines cardiovascular death, non-fatal myocardial infarction, and non-fatal ischemic stroke into one confirmed endpoint. Statistically, combining clinically relevant events can increase the number of endpoint events available for analysis. Interpretation still requires attention to the individual components because the three events represent different clinical outcomes.
What does a hazard ratio measure?
A hazard ratio compares the instantaneous rates at which the first qualifying event occurs between two randomized groups under the fitted time-to-event model. An HR below 1 would correspond to a lower estimated instantaneous event rate in the inclisiran group; an HR above 1 would correspond to a higher estimated rate. The hazard ratio does not directly state the absolute probability of having an event by a specific month.
Why is censoring important?
Not every participant will necessarily experience 3P-MACE during the period in which their outcome is observed. A participant can therefore contribute event-free follow-up until the point at which observation ends without a qualifying event. Survival methods incorporate this censored follow-up rather than treating it as equivalent to experiencing the endpoint.
Why is the proportional-hazards assumption relevant?
A Cox hazard ratio is most straightforward to interpret when the relative hazard between treatment groups is reasonably stable over time. If the treatment effect changes materially during follow-up, a single hazard ratio may conceal important temporal features of the treatment comparison. Time-specific event-free estimates can provide complementary information.
Why is the confidence interval important?
A confidence interval describes statistical uncertainty around an estimated treatment effect. A narrower interval indicates greater precision than a wider interval under the same statistical framework. The interval does not describe the range of effects that individual participants will experience.
8. Understanding the Primary Endpoint
| Component | Role in the primary endpoint |
|---|---|
| Cardiovascular death | One of the three confirmed components of 3P-MACE |
| Non-fatal myocardial infarction | One of the three confirmed components of 3P-MACE |
| Non-fatal ischemic stroke | One of the three confirmed components of 3P-MACE |
| First occurrence | The endpoint is defined by the first qualifying component event after randomization |
This structure means that the primary analysis is not a separate analysis of three independent primary endpoints. Instead, the registry defines a single composite time-to-first-event endpoint whose components are cardiovascular death, non-fatal myocardial infarction, and non-fatal ischemic stroke.
9. Analysis Population and Randomization
The registry identifies VICTORION-2P as a randomized trial with a parallel design, double masking, and two treatment arms. Randomization is fundamental to the interpretation of the eventual comparison because it establishes treatment assignment before subsequent follow-up and outcome observation.
The registry lists 17004 participants for enrollment. Because no arm-specific enrollment counts are reported in the registry information used here, an allocation ratio between the two treatment groups cannot be inferred.
10. Missing Data and Censoring
For a time-to-first-event endpoint, incomplete follow-up is handled differently from missing values in a conventional continuous or binary endpoint analysis. A participant who remains free of 3P-MACE while being observed can contribute event-free follow-up up to the point of censoring.
The registry information does not describe a specific missing-data or imputation strategy for the primary endpoint. In survival analysis, the validity of censoring assumptions is therefore an important consideration when interpreting the eventual treatment comparison.
11. Multiplicity and Multiple Components
The registry identifies one primary composite endpoint: time to first occurrence of 3P-MACE. Because the endpoint is defined as a composite, the three components are incorporated into the primary outcome rather than being presented as three separate primary endpoints in the registry description.
The registry information does not specify an alpha-allocation strategy, hierarchical testing procedure, or other multiplicity adjustment for additional hypotheses. No such procedure should therefore be inferred from the endpoint definition alone.
12. Interim Analysis
The registry information does not describe an interim statistical analysis, an alpha-spending procedure, or a group-sequential boundary for the primary endpoint.
If interim efficacy analyses are performed in a time-to-event cardiovascular-outcomes trial, the statistical interpretation of nominal p-values generally depends on the prespecified monitoring design. Repeated unadjusted testing can increase the probability of a false-positive conclusion, whereas a prespecified group-sequential framework can preserve control of the overall type I error.
The validity of interim inference depends on the prespecified testing and monitoring framework, not simply on whether a particular interim p-value crosses 0.05.
13. Safety and Secondary Endpoints
The registry information identifies the primary endpoint but does not provide posted statistical analyses or numerical safety results for the treatment arms in the information used for this page.
No arm-specific serious adverse-event counts or rates are reported here. Similarly, no secondary endpoint results are included because the registry information posted on ClinicalTrials.gov for the study does not provide posted statistical analyses for additional endpoints.
14. Clinical Biostats Interpretation of the Planned Analysis
If a hazard ratio is reported for 3P-MACE, it will summarize the relative rate at which the first qualifying cardiovascular event occurs in the inclisiran group compared with the placebo group under the specified survival model. The estimate will be a population-level treatment effect, not a guarantee about any individual participant's outcome.
A hazard ratio will not directly equal the percentage of participants who avoid cardiovascular events, the absolute reduction in event probability, or the percentage reduction in individual patient risk. Those questions require absolute event estimates at defined time points or other clinically interpretable measures.
The confidence interval around a future hazard-ratio estimate will indicate the statistical precision of the estimated relative treatment effect. A wide interval would indicate greater uncertainty, while a narrower interval would indicate greater precision under the same modeling framework.
A p-value addresses the compatibility of the observed data with a specified null hypothesis under the statistical model. It does not quantify the magnitude or clinical importance of the treatment effect. Effect size, confidence interval, absolute event rates, and follow-up duration provide complementary information.
The registry defines follow-up from randomization through total follow-up time of up to 72 months. Because participants may contribute different amounts of observed follow-up, the treatment comparison must account for censoring and the timing of first events rather than relying only on a simple proportion of participants with events.
15. What the Registry Currently Tells Us Statistically
| Question | Registry information |
|---|---|
| What is being tested? | Time to first occurrence of confirmed 3P-MACE |
| What constitutes 3P-MACE? | Cardiovascular death, non-fatal myocardial infarction, and non-fatal ischemic stroke |
| When is time measured? | From randomization to total follow-up time, up to 72 months |
| How is the study structured? | Randomized, parallel, double-blind, two-arm phase 3 trial |
| How many participants are planned? | 17004 |
| What treatments are compared? | Inclisiran sodium 300 mg and placebo |
| Are statistical results posted? | No formal statistical analyses are posted on ClinicalTrials.gov |
| Are treatment-effect estimates available in the registry information? | No |
| Are confidence intervals and p-values available? | No |
The statistical structure is therefore substantially clearer than the current numerical evidence available in the registry. The endpoint is explicitly defined, its time frame is specified, and the randomized comparison is identified, but the registry does not currently provide a posted estimate of the treatment effect.
16. Important Limitations and Interpretation Issues
- No posted treatment-effect estimate: the registry information does not provide a hazard ratio, confidence interval, or p-value for the primary endpoint.
- No posted event counts: the registry information does not provide the number of 3P-MACE events in each treatment arm.
- No posted absolute event estimates: event-free survival probabilities at specific time points are not reported in the registry information used here.
- No posted component-specific results: the registry defines cardiovascular death, non-fatal myocardial infarction, and non-fatal ischemic stroke as components of 3P-MACE, but does not provide component-specific statistical results here.
- No arm-specific enrollment counts: the registry lists total enrollment of 17004 and two treatment arms but does not provide arm-specific enrollment counts in the ClinicalTrials.gov record.
- No detailed missing-data strategy: the registry information does not specify an imputation or censoring strategy beyond defining the primary time frame.
- No interim-analysis framework: the registry information does not describe interim efficacy monitoring or alpha spending.
- Composite interpretation: 3P-MACE combines three distinct clinical outcomes, so eventual interpretation should consider both the composite and its individual components when those results become available.
17. Why This Trial Matters Statistically
VICTORION-2P provides a useful example of a large cardiovascular randomized trial built around a clinically meaningful composite time-to-event endpoint. The statistical challenge is not simply determining whether an event occurred, but analyzing when the first event occurred while accounting for varying follow-up and censoring.
| Concept | How it appears in VICTORION-2P |
|---|---|
| Randomization | Participants are randomized to inclisiran or placebo |
| Double masking | The registry identifies the study as double masked |
| Parallel design | Two treatment groups are followed in parallel |
| Time-to-event analysis | The primary endpoint is defined as time to first 3P-MACE occurrence |
| Composite endpoint | Cardiovascular death, non-fatal myocardial infarction, and non-fatal ischemic stroke form 3P-MACE |
| Kaplan-Meier estimation | Provides a natural framework for estimating event-free survival over time |
| Hazard ratio | Provides a relative measure of the instantaneous event rate between randomized groups |
| Censoring | Allows participants without an observed event to contribute their available follow-up |
| Longitudinal follow-up | The registry specifies total follow-up of up to 72 months |
| Large randomized population | The registry lists enrollment of 17004 participants |
18. Statistical Concepts in This Trial
Time-to-event endpoint
The primary outcome measures time from randomization to the first qualifying 3P-MACE event.
Composite endpoint
Three cardiovascular outcomes are combined into a single primary endpoint.
Randomized comparison
Inclisiran sodium 300 mg is compared with placebo under randomized treatment assignment.
Censoring
Survival analysis accommodates participants who remain event-free during their observed follow-up.
19. Trial Timeline
Study start
The registry lists 2021-11-23 as the study start date.
Active, not recruiting
The registry currently identifies VICTORION-2P as active, not recruiting.
Primary completion date
The registry lists 2027-05-10 as the primary completion date.
20. Planned Analysis: A Worked Statistical Framework
Although numerical treatment-effect results are not posted in the registry, the endpoint definition allows the statistical workflow to be described clearly.
At the participant level, follow-up begins at randomization. If cardiovascular death, non-fatal myocardial infarction, or non-fatal ischemic stroke occurs first, the participant contributes a 3P-MACE event at that time. If no qualifying event is observed during the available follow-up, the participant contributes censored event-free time. The resulting data structure is suitable for Kaplan-Meier estimation and a treatment-group comparison using a time-to-event model.
The primary endpoint is therefore fundamentally different from a simple binary endpoint such as "3P-MACE occurred: yes/no" because the timing of the first event contributes to the analysis.
21. What Should Be Reported With the Final Analysis?
When the primary results become available, a statistically complete interpretation of this endpoint would ordinarily benefit from several complementary measures rather than a single p-value.
| Measure | Statistical purpose |
|---|---|
| Number of 3P-MACE events | Describes the amount of observed primary-endpoint information |
| Kaplan-Meier event-free estimates | Shows absolute event-free probabilities over time |
| Hazard ratio | Summarizes the relative time-to-event treatment effect |
| Confidence interval | Quantifies statistical uncertainty around the treatment-effect estimate |
| P-value | Assesses the data against the specified null hypothesis under the chosen testing framework |
| Component event results | Shows how cardiovascular death, non-fatal myocardial infarction, and non-fatal ischemic stroke contribute to the composite |
| Follow-up distribution | Provides context for the amount and duration of observation |
Reporting these measures together helps separate the questions of how large the estimated treatment effect is, how precisely it is estimated, and how the observed data relate to the prespecified statistical hypothesis.
22. Clinical Interpretation vs Statistical Interpretation
Statistical interpretation
The registry defines a randomized, double-blind, parallel-group comparison with a time-to-first-event primary endpoint. The appropriate analytical framework is survival analysis, with treatment effects typically expressed using time-to-event measures such as a hazard ratio.
Clinical interpretation
The primary endpoint combines cardiovascular death, non-fatal myocardial infarction, and non-fatal ischemic stroke. Any eventual clinical interpretation should therefore consider the composite outcome together with the individual component outcomes and absolute event experience.
23. Why a Composite Endpoint Requires Careful Interpretation
A composite endpoint can be statistically efficient because several clinically relevant events contribute to a single outcome. However, the clinical meaning of the treatment comparison depends on the components as well as the composite.
Statistical advantage
Combining multiple qualifying outcomes can provide more endpoint events for the time-to-event comparison than analyzing a single component alone.
Interpretive caution
The component events can differ in clinical importance and frequency. A composite result should therefore not automatically be interpreted as though every component contributed equally.
For VICTORION-2P, the registry explicitly defines the three components, allowing the primary endpoint to be understood as a single time-to-first-event outcome rather than three unrelated primary hypotheses.
24. Current Evidence Status
Primary endpoint status
The registry identifies time to first occurrence of 3P-MACE as the primary endpoint.
No treatment-effect estimate, confidence interval, or p-value is posted in the ClinicalTrials.gov statistical-analysis information.
This distinction is important. A clearly specified endpoint and a large randomized design describe the structure of the evidence, but they do not themselves establish the direction or magnitude of a treatment effect. Those conclusions require the eventual observed event data and prespecified statistical analysis.
25. Sources
- ClinicalTrials.gov: NCT05030428 — VICTORION-2P.
Continue through the Clinical Biostats clinical trial library
Explore additional clinical trial statistical analyses and educational resources covering trial design, endpoints, survival analysis, and statistical methodology.
26. Record Summary
VICTORION-2P is a phase 3, randomized, double-blind, parallel-group study in participants with established cardiovascular disease and the registry-listed condition of atherosclerotic cardiovascular disease. The trial compares inclisiran sodium 300 mg with placebo and lists enrollment of 17004 participants. Its primary endpoint is time from randomization to the first confirmed occurrence of 3-point major adverse cardiovascular events, defined as cardiovascular death, non-fatal myocardial infarction, or non-fatal ischemic stroke, with follow-up of up to 72 months.
Statistically, the trial is a time-to-first-event problem. The central analytical concepts are randomization, censoring, Kaplan-Meier estimation, log-rank comparison, and hazard-ratio modeling. The registry does not currently post formal statistical analyses or numerical treatment-effect results for the primary endpoint, so the present statistical interpretation focuses on the endpoint structure and the framework that will be used to understand the eventual evidence.